Why insider trading matters?

Numerous studies have examined whether there is evidence that U.S. insiders systematically trade on private information despite the legal deterrence. The consensus appears to be that insider purchases (but not sales) tend to be followed by positive abnormal stock price performance, particularly for small growth stocks.

- Prof. B. Espen Eckbo, Dartmouth College
AGIOS PHARMACEUTICALS, INC. (AGIO)
Sector: Healthcare; Industry: Biotechnology

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of hematologic malignancies, solid tumors, and rare genetic diseases. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2021-04-15 Alenson Carman Principal Accounting Officer Sell 991 $54.00 $53,514 No
2021-03-05 Miles Darrin Chief Commercial Officer Sell 2,700 $48.10 $129,868 No
2020-09-02 Alenson Carman Principal Accounting Officer Sell 250 $39.93 $9,982 No
2020-05-20 Bowden Christopher Chief Medical Officer Sell 3,583 $50.01 $179,200 Yes
2020-03-02 Alenson Carman Principal Accounting Officer Sell 345 $47.30 $16,318 No
2020-02-26 Alenson Carman Principal Accounting Officer Sell 472 $47.12 $22,241 No
2020-02-20 Alenson Carman Principal Accounting Officer Sell 2,427 $53.37 $129,529 No
2020-02-13 Bowden Christopher Chief Medical Officer Sell 7,100 $50.16 $356,112 Yes
2020-02-11 Bowden Christopher Chief Medical Officer Sell 621 $50.02 $31,063 Yes
2020-02-05 Bowden Christopher Chief Medical Officer Sell 49,638 $50.08 $2,485,989 Yes
2019-12-26 Alenson Carman Principal Accounting Officer Sell 2,950 $50.09 $147,766 No
2019-11-13 FOUSE JACQUALYN A Chief Executive Officer Buy 40,322 $31.00 $1,249,982 No
2019-11-13 Schenkein David P Director Buy 8,064 $31.00 $249,984 No
2019-11-12 CELGENE CORP /DE/ 10%-Owner Buy 403,225 $31.00 $12,499,975 No
2019-04-05 Biller Scott Chief Scientific Officer Sell 3,000 $67.71 $203,135 Yes
2019-04-01 Bowden Christopher Chief Medical Officer Sell 10,000 $66.57 $665,747 Yes
2019-03-15 Bowden Christopher Chief Medical Officer Sell 10,000 $64.16 $641,615 Yes
2019-03-05 Biller Scott Chief Scientific Officer Sell 3,000 $67.68 $203,032 Yes
2019-03-04 Hoerter Steven L. Chief Commercial Officer Sell 10,000 $67.00 $670,050 Yes
2019-02-27 Biller Scott Chief Scientific Officer Sell 9,000 $65.00 $585,000 Yes
2019-02-19 Alenson Carman Principal Accounting Officer Sell 152 $76.45 $11,620 Yes
2018-11-05 Biller Scott Chief Scientific Officer Sell 3,000 $69.69 $209,071 Yes
2018-10-05 Biller Scott Chief Scientific Officer Sell 3,000 $69.79 $209,377 Yes
2018-09-12 MARAGANORE JOHN Director Sell 27,717 $72.23 $2,002,110 No
2018-09-05 Alenson Carman Principal Accounting Officer Sell 312 $83.00 $25,896 Yes
2018-09-05 Biller Scott Chief Scientific Officer Sell 3,000 $83.07 $249,215 Yes
2018-08-30 Bowden Christopher Chief Medical Officer Sell 2,000 $80.03 $160,051 Yes
2018-08-24 Hoerter Steven L. Chief Commercial Officer Sell 2,050 $74.92 $153,586 Yes
2018-08-06 Biller Scott Chief Scientific Officer Sell 3,000 $80.11 $240,333 Yes
2018-07-25 Hoerter Steven L. Chief Commercial Officer Sell 2,050 $84.58 $173,389 Yes

Insider Smart

Celldex Therapeutics, Inc. (CLDX) - Multiple insiders including President, EVP, CEO, CSO and Directors bought shares on Jun.9th, first time since 2018, this was very convincing and we initiated a position. Stock soared from $3 to 9$ in 2 days, and the run is still going on.

Insider Smart

Axsome Therapeutics, Inc (AXSM) - AXSM shows the power of an #allgreen stock, no insider selling, great management great company, if you follow the insiders last year and pick up around $25, the 52 week high is $100+.